67% subjects of group A had partial response
One partial response
was not able to be confirmed because the patient's CT scan was confounded by a lung collapse, limiting the radiologist's ability to distinguish the actual tumor size.
In the randomized, multicenter trial, 54% of 147 patients had an objective, partial response
to therapy with either 400 or 600 mg of imatinib mesylate per day; no patient responded completely, however.
The partial responses
were durable with a median duration of over eight months.
were achieved in 10 of these patients (29%), and 5 of these patients had a partial response
at the first radiologic assessment.
Of the 38 patients assessed, 12 patients (32%) had a RECIST criteria partial response
(PR), 22 patients (58%) achieved stable disease (SD) and 4 patients (10%) had progressive disease (PD).